Next Generation Specialty Ophthalmics

Vinci Pharmaceuticals

Disrupting retinal disease treatment with EPIPLANT™, a proprietary needle free drug delivery platform.

CONTACT
Next Generation Specialty Ophthalmics

Vinci Pharmaceuticals

Disrupting retinal disease treatment with EPIPLANT™, a proprietary needle free drug delivery platform.

CONTACT
Next Generation Specialty Ophthalmics

Vinci Pharmaceuticals

Disrupting retinal disease treatment with EPIPLANT™, a transformative and needle free platform technology.

WHO we ARE
Architecture Firm - Architect X Webflow Template
Who We Are

Transforming the treatment of retinal diseases

Get in Touch

Vinci Pharmaceuticals is a specialty ophthalmic pharmaceutical company motivated to disrupt the treatment of retinal diseases with novel, next generation platform technologies. Our proprietary solution is EPIPLANT™, a transformative platform technology that provides safe, effective and needle free drug delivery to the retina.

Vinci Pharmaceuticals is operated by a proven and committed leadership team with extensive experience in commercial strategy and clinical development in retinal diseases. They are joined by a Scientific Advisory Board of world-renowned experts with extensive drug development and vitreoretinal expertise.

The Problem

Lack of needle-free therapies in growing markets

Diabetic Macular Edema (DME) and Intermediate AMD (iAMD) are prominent and growing causes of vision loss in the United States. Current therapies lack durability and are avoided because of their frequent injections. In other words, most patients don't like a needle in the eye.

We Started Back In 2012 - Architect X Webflow Template
We Started Back In 2012 - Architect X Webflow Template
Our Solution

EPIPLANT™

EPIPLANT™ is a disruptive, next generation proprietary platform technology for the treatment of retinal diseases. It provides safe, effective drug delivery to the retina, has a clear regulatory pathway and strong IP protection.

Most importantly, it's needle free.
Contact Vinci

Significant Market Opportunities

Poised for disruption by Vinci's next generation pipeline
>$2B
Diabetic Macular Edema Market Potential
DME is the most common cause of vision loss in patients with diabetes, with onset as early as 40 years old.
50%
of patients do not respond to current DME Therapies¹
By 2050, the number of patients with DME in the US is expected to double to 14.6M.
>$10B
intermediate AMD
Market Potential
No therapy is currently approved for the treatment of iAMD.
50%
of the amd market is intermediate
~11M patients in the US are currently affected by AMD.² It is the leading cause of severe vision loss in ages 60+.
1. Gonzalez et al. (2016) Am J Ophthalmol, 172:72-79. 2. Mulligan K, et al. JAMA Opthalmol. 2020; 138(1):40-47.
Proven Leadership Team

Meet Our Co-Founders

Contact Our Team
CO-Founder
Karl Csaky, M.D., Ph.D.
Karl Csaky, M.D., Ph.D. is Managing & Chief Medical Director of the Retina Foundation of the Southwest (RFSW). He serves as T. Boone Pickens Director for the Molecular Ophthalmology Laboratories and Clinical Center of Innovation for Macular Degeneration. Karl also serves on the Scientific Advisory Boards of Roche, Allergan, Johnson & Johnson, Genentech, Regeneron, Merck, and Novartis.
CO-Founder, CEO
Philip A. Gioia
Philip Gioia is the CEO and Director of Eye Therapies. He serves on the Executive Pharma Team at Bausch & Lomb, is a Board Advisor to TearClear & Ocugen, and is the Executive in Residence at Warburg Pincus.

Investment Highlights

Significant Market Opportunities

Vinci's pipeline addresses growing markets for treatments of Diabetic Macular Edema (>$2B potential) and Intermediate AMD (>$10B potential). Both markets lack safe, durable and needle free therapies.

Learn MOre

Transformative Platform Technology

EPIPLANT™, Vinci's proprietary and next generation platform technology, meets these underserved markets with safe, effective, needle free drug delivery to the retina. It has a clear regulatory pathway and strong IP protection.

Learn MOre

Proven Leadership

Vinci Pharmaceuticals is operated by a proven and committed leadership team with extensive experience in commercial strategy and clinical development in retinal diseases.

They are joined by a Scientific Advisory Board of world-renowned experts with extensive drug development and vitreoretinal expertise.

Learn MOre
Learn More
Contact us

Contact Us

For questions and inquiries, please contact Vinci Pharmaceuticals using the form below.

Thank you

Thanks for reaching out. We will get back to you soon.
Oops! Something went wrong while submitting the form.